Seropositive Blood Research Articles

Response Patterns and Behavior of Seropositive Blood Donors: A Comprehensive Analysis.

Background Blood transfusion services are vital in healthcare, ensuring a steady and safe supply of blood for patients in need. Identifying seropositive blood donors and understanding their response patterns and behaviors are critical for improving the safety and efficacy of blood transfusion practices. Aim Our study aims to determine the response rate and pattern of blood donors who test reactive for transfusion-transmitted infections (TTIs) and to understand the attitudes of reactive blood donors toward post-donation notification, follow-up, and counseling. Materials and methods Our study is retrospective audit analyzing the data record for a period of 24 months from October 2021 to October 2023 in the transfusion medicine department of a tertiary care hospital in southern India. All donations were screened for hepatitis B, hepatitis C, HIV, malaria, and syphilis. Results Of the total 8,276 donations during the study period, 117 (1.41%) were reactive for various TTIs. The highest prevalence was hepatitis B (0.61%), followed by hepatitis C (0.38%), then HIV (0.22%) and syphilis (0.14%). Of all the TTI reactive donors, 82 donors (70%) responded after communication, and the remaining 30% could not be contacted by any mode of communication. The most common reason for non-communication was the fabricated postal address given by the donors. Of the donors approached, 57 (48.7%) reinstated to our blood bank for further counseling and specific treatment. The donor's busy schedule and out-of-city residence were the main reasons for non-compliance with the follow-up protocol. Conclusion Informing donors of their serological status and providing post-donation counseling are crucial elements of blood transfusion protocol. Necessary knowledge about TTIs are to be instilled to the donors during the blood collection procedure. Moreover, its crucial for the donor to provide accurate demographic details aiding follow up and easy access during times of managing blood inventory.

Seroprevalence of Transfusion Transmitted Infection (TTI) and demographic profile of seropositive blood donors in a tertiary care hospital

Seroprevalence of Transfusion Transmitted Infection (TTI) and demographic profile of seropositive blood donors in a tertiary care hospital

Current Resistance of HIV-1 Strains Isolated in Volunteer Blood Donors in Gabon.

Detection of drug resistance mutations (DRMs) and HIV-1 subtypes ensures effective therapeutic management for HIV-infected individuals. In Gabon, data on DRMs are very little available in the population of people living with HIV and also among voluntary HIV-positive blood donors. This study aimed to study subtypes and DRMs in HIV-1-positive volunteer blood donors in Gabon. A cross-sectional study was carried out at the National Blood Transfusion Center of Gabon. A purposive sampling method was used to collect 128 HIV-1 seropositive blood samples. Viral RNA was extracted on real-time PCR (Abbott 2000®), and sequencing was performed on ABI 3500 (Hitachi®). SPSS version 21.0 software was used for statistical analysis. Of the 128 seropositive volunteer donors included, men and the 29-39-age group were more representative at 78.9% and 49.2%, respectively. Eighty-two samples were sequenced. The majority strains identified were subtype A, subtype F, subtype G, CRF02_AG, and CRF45_cpx. The resistance mutations identified were K103N, L210W, E138G, V179D, V179T, and M46L. The prevalence of resistant subtypes was 25.6%. CRF02_AG strains exhibited high-level resistance to non-nucleoside reverse transcriptase inhibitors (NNRTIs), including efavirenz and nevirapine. The study identified major DRMs in reverse transcriptase and protease that confer high-level resistance to most NNRTIs, nucleoside reverse transcriptase inhibitors, and protease inhibitors. CRF02_AG was more predominant, and the frequency of resistant subtypes was high. However, these data will contribute to the therapeutic choice during the initiation of antiretroviral treatment in treatment-naive patients in Gabon.

Demographic Distribution Pattern and Antiretroviral Therapy Status Among HIV Patients in Selected Tertiary Hospitals in Abeokuta, Ogun State

The occurrence of human immunodeficiency virus (HIV) in Nigeria is relatively high and compromised with low antiretroviral therapy (ART) coverage. The study aimed at investigating the effect of ART on the CD4 cell count among seropositive individuals. Blood samples of HIV patients visiting three referral hospitals in Abeokuta were collected and CD4 cell count determined via flow cytometry method. Socio-demographic data of patients were also collected and analyzed using STATA/IC. A total of 615 seropositive blood samples were collected from three hospitals. The female to male ratio was found to be 2:1 of which age bracket 20-40 years had the highest infective number (63.3%) among other age categories. There was higher HIV occurrence among the married (52%) than the single (26.8%), while those with primary or secondary education had the highest (42.4%) compared to tertiary education (36.7%) and no formal education (9.1%). The CD4 count of infected cases showed that 51.2% had CD4 count between 100-200 cells/µL with 5.2% above 200 cells/µL. Also only 47.3% of the total infected cases placed on ART had a mean CD4 cell count (132.1±4.23) higher than those not on ART (CD4 count = 98.67±3.56). As a way of effectively managing HIV in Ogun State and meeting the 2030 set goal of USAIDS there is need for more HIV screening for early commencement of ART towards suppressing viral load.

Epstein-Barr virus reactivation is not causative for post-COVID-19-syndrome in individuals with asymptomatic or mild SARS-CoV-2 disease course

PurposePost-COVID-19-Syndrome (PCS) frequently occurs after an infection with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). However, the understanding of causative mechanisms is still limited. Aim of this study was to determine the PCS rate among SARS-CoV-2 seropositive blood donors as representatives of supposedly healthy adults, who had experienced an asymptomatic or mild COVID-19 disease course, and to examine whether Epstein-Barr virus (EBV) is reactivated in individuals reporting PCS.MethodsThe PCS rate was determined using questionnaires that included questions about infection and persistent symptoms. Pre-pandemic blood samples and samples collected at regular, pre-defined times after a SARS-CoV-2 infection were analysed for neopterin, a marker for antiviral immune responses, by an enzyme-linked immunosorbent assay (ELISA). Additionally, we determined the rate of SARS-CoV-2 anti-N total antibodies using an electrochemiluminescence immunoassay (ECLIA). Furthermore, quantitative real-time polymerase chain reaction (qPCR) to detect EBV DNA and ECLIA screening for EBV viral capsid-antigen (VCA) IgM, IgG and EBV nuclear antigen 1 (EBNA) IgG were performed.ResultsOur data reveal that 18% of all infections result in PCS, with symptoms lasting for up to one year. In individuals reporting PCS, no elevated levels of neopterin were detected, indicating no persisting pro-inflammatory, antiviral immune response. SARS-CoV-2 antibody levels were declining in all participants in comparable manner over time, pointing to a successful virus clearance. In individuals with PCS, no EBV DNA could be detected. Furthermore, no differences in EBV specific antibody levels could be shown in PCS groups compared to non-PCS groups.ConclusionOur data suggest that PCS in per se healthy, immunocompetent adults cannot be ascribed to a reactivation of EBV.

Correlation between Hepatitis B Viral Load and Hepatitis B Surface Antigen Levels in Asymptomatic Seropositive Blood Donors

Background and Objectives: Correlation has been shown between hepatitis B surface antigen (HBsAg) and hepatitis B virus (HBV) levels in different patient categories. However, this has not been studied for donors. The aim of this study was to study the relationship between HBV DNA levels and E ratio obtained for HBsAg testing by chemiluminescence immunoassay (CLIA) performed on donor samples. Methods: A prospective, observational study was conducted in the department of transfusion medicine at a large tertiary health-care setup in North India from 2017 to 2021. Serological testing for HBV included HBsAg testing by CLIA. All reactive samples were tested in duplicate by electro CLIA (eCLIA). All samples found to be reactive in all three tests were then tested by a rapid diagnostic test and quantitative polymerase chain reaction. Results: During the study duration, 251 donors were found to be reactive for HBsAg by CLIA and eCLIA in screening. Of these 251, HBV DNA could not be detected in 85 (33.86%) samples, whereas in rest 166 (66.14%) samples, HBV DNA was detected. Mean E ratio for CLIA for all 251 samples was 5177.45, whereas mean viral copies detected were 19645858.66. The correlation for all 251 samples was found to be weak negative. The correlation for sero-reactive samples with the presence of HBV DNA was also found to be weak negative. Conclusion: In conclusion, we found significant but weak correlation between HBsAg results obtained by CLIA and HBV DNA levels for blood donors. The measurement of HBV DNA level is necessary for all apparently healthy donors coming for blood donation and testing reactive for HBsAg in screening assays.

Analysis of a German blood donor cohort reveals a high number of undetected SARS-CoV-2 infections and sex-specific differences in humoral immune response.

Seroprevalence studies can contribute to a better assessment of the actual incidence of infection. Since long-term data for Germany are lacking, we determined the seroprevalence of immunoglobulin G (IgG) antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in residual plasma samples of 3,759 German regular blood donors between July 2020 and June 2021. Over almost the entire study period, the incidences determined based on our data were higher than those officially reported by the Robert Koch Institute, the public health institute in Germany. Using our serological testing strategy, we retrospectively detected natural infection in 206/3,759 (5.48%; 95% confidence interval (CI): 4.77-6.25) individuals. The IgG seroprevalence ranked from 5.15% (95% CI: 3.73-6.89) in Lower Saxony to 5.62% (95% CI: 4.57-6.84) in North Rhine Westphalia. The analyses of follow-up samples of 88 seropositive blood donors revealed a comparable fast decay of binding and neutralizing anti-SARS-CoV-2 IgG antibodies. The antibody avidity remained at a low level throughout the whole follow-up period of up to 181 days. Interestingly, female donors seem to express a stronger and longer lasting humoral immunity against the new coronavirus when compared to males. Conclusion: Overall, our data emphasizes that seroprevalence measurements can and should be used to understand the true incidence of infection better. Further characterization of follow-up samples from seropositive donors indicated rapid antibody waning with sex-specific differences concerning the strength and persistence of humoral immune response.

Hepatitis E Virus Prevalence Amongst Blood Donors in Kenya

Introduction: Hepatitis E (HEV) is an emerging cause of viral hepatitis mainly transmitted through the fecal-oral and parenteral routes. It has greatly affected populations in many parts of Kenya due to declined sanitation practices. The objective of the research was to determine IgM and IgG seroprevalence of HEV prevalence among blood donors in Kenya as well as its Anti-HEV sero-reactivity by demographic factors.
 Material and Methods: Cross sectional research design was used to collect blood samples from six from regional blood collecting centers, with blood donors selected through proportionate stratified sampling. Serum were matched to the age and gender distribution of the blood donors and tested by IgM and IgG enzyme immunoassays (EIA). The screening was carried out using human MP Diagnostics (0721150096T-96 wells) HEV ELISA kit. To test for IgM and IgM anti-HEV antibodies, microplates with 96-well plate were used. Results were averaged to generate a signal-to-noise ratio with ≥1.0 designated as positive per the manufacturer’s recommended cutoff.
 Result and Conclusion: On the analysis, IgM reactivity was associated with HEV (RR 1.66, 95%CI 1.07, 2.60; p = 0.024) while IgG reactivity was associated with increasing age (p < 0.001) and HIV (RR 1.93, 95%CI 1.52, 2.46; p < 0.001). AFI case-patients were more likely to be IgM (p = 0.002) and IgG (p<0.001) reactive compared to healthy residents. All the 19 hepatitis E virus IgM and/or IgG seropositive blood samples tested negative for HEV RNA since no bands were detected using RT-PCR technique. Serologic evidence for HEV in blood samples from selected areas suggests a high burden of infection, though age and gender exhibited no significant difference in prevalence of HEV among the blood donors in Kenya (p>0.05).

Seroprevalence of Trypanosoma cruzi in Eight Blood Banks in Mexico

The true prevalence of Chagas disease in Mexico is unknown. However, it has been estimated that 1.1-4 million people are infected with Trypanosoma cruzi, which represents a potential risk for transmission of the disease via contaminated blood. To determine the Chagas disease seroprevalence in donors from eight blood banks in the north of Mexico City, and the northeast of the State of Mexico. Serum samples from blood donors (n=515,038) were tested to detect the presence of anti-Trypanosoma cruzi antibodies in eight blood banks. The serologic screening test was performed in each of the blood banks. To confirm the seropositive blood donors, only two out of the eight blood banks used a test with a different principle with the aim of identifying anti-Trypanosoma cruzi antibodies. All tests were validated by the Mexican Institute for Epidemiological Diagnosis and Reference. One thousand two hundred and ten blood donors were seropositive for Trypanosoma cruzi, which represents a 0.23% seroprevalence (95% CI 0.22-0.25%). Of the seropositive blood donors, 97.03 % resided in the northeast area of the State of Mexico, Mexico City, and southern part of the State of Hidalgo. Active transmission of Chagas disease may be occurring in non-endemic regions in the northeast of the State of Mexico.

Evidence of likely autochthonous Chagas disease in the southwestern United States: A case series of Trypanosoma cruzi seropositive blood donors.

BackgroundChagas disease is a parasitic infection that can insidiously cause non‐ischemic cardiomyopathy. Given the largely silent nature of this progressive disease, asymptomatic blood donors pose potential blood transfusion risk. Blood donation screening has become an unintentional form of Chagas disease surveillance, with thousands of new cases identified since national surveillance was initiated in 2007.Study Design and MethodsWe recruited T. cruzi‐positive blood donors identified from California and Arizona blood centers for confirmatory blood screening and assessment of lifetime infection risk.ResultsAmong eight suspected cases, we identified four confirmed US autochthonous infections. The current manuscript details the transmission sources, healthcare‐seeking behaviors post‐blood donation resulting, and clinical course of disease among persons without any history of travel to endemic Latin American countries.DiscussionThis manuscript presents four additional US‐acquired Chagas disease cases and identifies an opportunity for blood centers to assist in confronting barriers surrounding Chagas disease in the US.

Performance of a rapid immuno-chromatographic test (Schistosoma ICT IgG-IgM) for detecting Schistosoma-specific antibodies in sera of endemic and non-endemic populations

BackgroundSchistosomiasis, an acute and chronic parasitic disease caused by human pathogenic Schistosoma species, is a neglected tropical disease affecting more than 220 million people worldwide.For diagnosis of schistosomiasis, stool and urine microscopy for egg detection is still the recommended method, however sensitivity of these methods is limited. Therefore, other methods like molecular detection of DNA in stool, detection of circulating cathodic antigen in urine or circulating anodic antigen in urine and serum, as well as serological tests have gained more attention. This study examines the sensitivity and specificity of a rapid diagnostic test based on immunochromatography (Schistosoma ICT IgG-IgM, LD Bio, Lyon, France) for simultaneous detection of specific IgG and IgM antibodies in serum, against Schistosoma spp. in endemic and non-endemic populations.Methodology/Principal findingsFrozen banked serum samples from patients with confirmed schistosomiasis, patients with other helminth infections, patients with seropositive rheumatoid arthritis and healthy blood donors were used to assess the sensitivity and the specificity of the Schistosoma ICT IgG-IgM rapid diagnostic test.The test showed a sensitivity of 100% in patients with parasitologically confirmed schistosomiasis, irrespective of the species (S. mansoni, S. haematobium, S. japonicum, S. mekongi). In healthy blood donors and patients with rheumatoid factor positive rheumatoid arthritis from Europe, specificity was 100%. However, in serum samples of patients with other tissue invasive helminth infections, the test showed some cross-reactivity, resulting in a specificity of 85%.Conclusion/SignificanceWith its high sensitivity, the Schistosoma ICT IgG-IgM rapid diagnostic test is a suitable screening test for detection of Schistosoma specific antibodies, including S. mekongi. However, in populations with a high prevalence of co-infection with other tissue invasive helminths, positive results should be confirmed with other diagnostic assays due to the test’s imperfect specificity.

Lack of plasma viremia in SARS-CoV-2 seropositive blood donors carrying the virus in nasopharyngeal swabs argues against potential transmission of COVID-19 through blood

article: Lack of plasma viremia in SARS-CoV-2 seropositive blood donors carrying the virus in nasopharyngeal swabs argues against potential transmission of COVID-19 through blood - Minerva Biotechnology and Biomolecular Research 2022 March;34(1):47 - Minerva Medica - Journals

Knowledge and Practice of Hepatitis B and C Prevention among Seropositive and Seronegative Prospective Blood Donors in a Tertiary Care Hospital in Eastern Nigeria

Introduction: Hepatitis B and C infections are endemic in Nigeria and the major causes of chronic liver diseases, including hepatocellular carcinoma. One of the major routes of transmission is by transfusion of infected blood or blood products. Awareness of the disease is important, and this study seeks to compare the knowledge and practice of the disease among the seropositive and seronegative prospective blood donors. Aim: To assess the difference in the level of knowledge and preventive practice of blood borne hepatitis among hepatitis B and hepatitis C seropositive and seronegative prospective blood donors. Materials and Methods: The present study was a descriptive survey carried out between June 2019 to January 2020 in the Blood Donor’s Department of the University of Nigeria Teaching Hospital, Enugu, Nigeria. A pretested self/interviewer’s administered questionnaire was used to assess the knowledge and practice among 100 hepatitis B and hepatitis C seropositive and 305 seronegative prospective blood donors. The hepatitis B and C seropositive subjects were screened using Enzyme Immunosorbent Assay (ELISA) technique. The findings and scores were analysed using IBM Corporation 2019 Statistical Package for the Social Sciences (SPSS) software version 21.0. Results: Total of 305 respondents were seronegative while 82 and 18 were hepatitis B and C seropositive, respectively. The mean age of the study participants was 27.78±7.17 years, whereas it was 28.09±6.36 years and 27.46±7.968 years among seropositive and seronegative respondents, respectively. In the study, 98 (98%) males and 2 (2%) females were in the seropositive group while, 268 (87.9%) males and 37 (12.1%) females were in seronegative group. The overall knowledge score and practice score were 56.3% and 28.1%, respectively. In the seropositive group, the average knowledge score was 27.3% and the average practice score was 17%. While in the seronegative group, the average knowledge score was 65.7% and the average score on practice score was 31.8%. There was a significant association between seropositive and being a male (p-value=0.001), less educated (p-value=0.002), currently unmarried (p-value=0.029), knowledge above average (p-value=0.001), and practice below average (p=0.002). None of the respondents had hepatitis B vaccination. Conclusion: Based on the results obtained from the present study, it is evident that the level of knowledge and practice among the seropositive respondent is significantly low when compared with the seronegative groups. There is a need for a serious awareness campaign on the transmission and prevention of hepatitis B and C, and the possibility of extending hepatitis B immunisation coverage in the country owing to the increasing burden of the disease.

Molecular detection of spotted fever group Rickettsia species from seropositive human blood samples

The Sri Lankan Journal of Infectious Diseases (SLJID) is an open access, peer-reviewed, biannual journal published by the Sri Lankan Society for Microbiology (SSM). The Journal considers articles from all professional disciplines involved in the field of infectious diseases. The Journal has been in publication since 2011, is included in the DOAJ since 2018 and is a member of COPE since 2021. The SLJID practices a double-blind peer review policy. From 2022, the SLJID publishes accepted manuscripts online immediately after copy-editing, enabling rapid dissemination of scientific knowledge. The published articles are subsequently compiled into two issues in April and October. The SLJID does not charge any article processing or publication fee.

Incidence and Predictors of Progression to Chagas Cardiomyopathy: Long-Term Follow-Up of Trypanosoma cruzi-Seropositive Individuals.

There are few contemporary cohorts of Trypanosoma cruzi-seropositive individuals, and the basic clinical epidemiology of Chagas disease is poorly understood. Herein, we report the incidence of cardiomyopathy and death associated with T. cruzi seropositivity. Participants were selected in blood banks at 2 Brazilian centers. Cases were defined as T. cruzi-seropositive blood donors. T. cruzi-seronegative controls were matched for age, sex, and period of donation. Patients with established Chagas cardiomyopathy were recruited from a tertiary outpatient service. Participants underwent medical examination, blood collection, ECG, and echocardiogram at enrollment (2008-2010) and at follow-up (2018-2019). The primary outcomes were all-cause mortality and development of cardiomyopathy, defined as the presence of a left ventricular ejection fraction <50% or QRS complex duration ≥120 ms, or both. To handle loss to follow-up, a sensitivity analysis was performed using inverse probability weights for selection. We enrolled 499 T. cruzi-seropositive donors (age 48±10 years, 52% male), 488 T. cruzi-seronegative donors (age 49±10 years, 49% male), and 101 patients with established Chagas cardiomyopathy (age 48±8 years, 59% male). The mortality in patients with established cardiomyopathy was 80.9 deaths/1000 person-years (py) (54/101, 53%) and 15.1 deaths/1000 py (17/114, 15%) in T. cruzi-seropositive donors with cardiomyopathy at baseline. Among T. cruzi-seropositive donors without cardiomyopathy at baseline, mortality was 3.7 events/1000 py (15/385, 4%), which was no different from T. cruzi-seronegative donors with 3.6 deaths/1000 py (17/488, 3%). The incidence of cardiomyopathy in T. cruzi-seropositive donors was 13.8 (95% CI, 9.5-19.6) events/1000 py (32/262, 12%) compared with 4.6 (95% CI, 2.3-8.3) events/1000 py (11/277, 4%) in seronegative controls, with an absolute incidence difference associated with T. cruzi seropositivity of 9.2 (95% CI, 3.6-15.0) events/1000 py. T. cruzi antibody level at baseline was associated with development of cardiomyopathy (adjusted odds ratio, 1.4 [95% CI, 1.1-1.8]). We present a comprehensive description of the natural history of T. cruzi seropositivity in a contemporary patient population. The results highlight the central importance of anti-T. cruzi antibody titer as a marker of Chagas disease activity and risk of progression.

Improvement of the understanding of blood donors with human T-cell leukaemia virus type 1 using a new information booklet.

BackgroundHuman T‐cell leukaemia virus type 1 (HTLV‐1) tests have been mandated in Japan since 1986, and notification of HTLV‐1‐seropositive donors started in 1999. However, donor knowledge and response to notification has not been assessed.Study design and MethodsA questionnaire survey was conducted among blood donors notified of HTLV‐1 seropositivity regarding their knowledge of HTLV‐1 and unmet information needs. To reduce anxiety among notified individuals and raise awareness of their infection status, we created a booklet containing information that would be useful for these individuals without causing unnecessary anxiety while also requesting that they refrain from donating blood in the future.ResultsA questionnaire survey conducted before the distribution of a new booklet revealed that 15.0% of respondents donated blood again despite receiving an HTLV‐1‐seropositive notification at the previous donation. While 62.2% of respondents reacted to the notification favourably, 40.2% expressed anxiety and 32.5% requested information on related diseases and medical institutions for consultation. In the secondary survey after distribution of the new booklet, 87.9% of respondents reported that the information was comprehensible, and an increase in consultations of medical institutions by notification recipients was observed. Furthermore, no re‐visiting donors were observed among the HTLV‐1‐seropositive recipients who were notified using the new information booklet.ConclusionThe new information booklet provided enlightenment on HTLV‐1 infection and facilitated the consultation of medical institutions by seropositive donors, leading to an improvement in the health‐related quality of life of seropositive blood donors and the safety of blood products.

Delayed-onset cytomegalovirus infection is frequent after discontinuing letermovir in cord blood transplant recipients

AbstractCytomegalovirus (CMV)-seropositive umbilical cord blood transplantation (CBT) recipients have a high incidence of CMV-associated complications. There are limited data regarding the efficacy of letermovir for preventing clinically significant CMV infection (CS-CMVi), and the impact of letermovir prophylaxis on delayed-onset CMV reactivation after letermovir discontinuation, in CBT recipients. We compared the cumulative incidence of CS-CMVi and CMV detection in 21 CMV-seropositive CBT recipients receiving letermovir prophylaxis with a historical cohort of 40 CBT recipients receiving high-dose valacyclovir prophylaxis. Letermovir was administered on day +1 up to day +98. The cumulative incidence of CS-CMVi was significantly lower by day 98 in the letermovir cohort (19% vs 65%). This difference was lost by 1 year due to a higher incidence of delayed-onset CMV reactivation in the letermovir cohort. No patients developed CMV disease in the letermovir cohort within the first 98 days compared with 2 cases (2.4%) in the high-dose valacyclovir cohort; 2 patients developed CMV enteritis after discontinuing letermovir. Median viral loads were similar in both cohorts. Thus, letermovir is effective at preventing CS-CMVi after CBT, but frequent delayed-onset infections after letermovir discontinuation mandate close monitoring and consideration for extended prophylaxis.

Changing trends in seroprevalence rates of transfusion-transmitted diseases among blood donors in Jordan

BackgroundHepatitis B and C infections and transmission are a serious challenge to all healthcare systems. We studied seroprevalence rates of Transfusion Transmitted Diseases (TTD) among blood bank donors in Jordan from 2014 to 2019 as a follow-up study of our previously published work. In addition, we wanted to explore the efficacy of the mandatory vaccination of infants against hepatitis B virus (HBV) which was implemented by the Ministry of Health since 1995 for the eradication of HBV infection in Jordan.MethodsWe reviewed blood bank donors’ records at King Hussein Cancer Center (KHCC) from January 1st, 2014, until December 31st, 2019. Results of seropositivity prevalence rates for HBsAg, anti-HBcore, and anti-HCV, using Enzyme-Linked ImmunoSorbent Assay (ELISA) were compared to seropositivity rates from our previously published data. In addition, our results were compared to data obtained from other blood banks in Jordan, as well as compared to published information from blood banks in neighboring countries.ResultsThe prevalence rates (%) of seropositive blood donors for viral hepatitis for the years 2014, 2015, 2016, 2017, 2018, and 2019, were as follows: HBsAg rates were 0.3386, 0.2108, 0.1801, 0.1898, 0.2068, and 0.2741; anti-HBcore rates were 4.1112, 3.2271, 2.9748, 2.8405, 2.6879 and 3.0986; and anti-HCV rates were 0.1129, 0.0486, 0.0548, 0.0654, 0.0782, and 0.0839, respectively. There was a significant increase in the prevalence of HBsAg, Anti-HBcore and Anti-HCV antibodies in 2019 (one sample z-score test, p < 0.00001).ConclusionsPrevalence rates of hepatitis B and C infections among Jordanian blood bank donors showed a steady decline between 2009 and 2017, and these rates were much lower in Jordan than in neighboring countries. However, an increase in the prevalence rates of hepatitis B and C infections among blood bank donors was documented in 2019. While the reasons for this increase are not clear yet, these findings highlight the importance of renewed efforts to increase public health awareness of HBV and implement effective measures to prevent the transmission and infection with HBV, including national vaccination programs.

A retrospective study on seroprevalence of Transfusion Transmitted Infections in blood donors at Dhiraj Hospital, Vadodara

Background: Transfusion of blood and its components help in saving lives but it can also be a life-threateninghazard. Prevention of transmission of infectious diseases through blood transfusion in developing countriesis difficult, since the resources available are limited.Methods and Material: A retrospective study was undertaken to determine the seroprevalence of TTIamong the blood donors who donated blood to Dhiraj Hospital Blood Bank between January 2015 andDecember 2019.The TTI reports of the donors was obtained from the blood donor data records.Each blood unit was tested by ELISA method for HIV, Hepatitis B and Hepatitis C virus. Syphilis was testedby Rapid Plasma Reagin (RPR) card test. Malaria was tested by antigen rapid diagnostic test.As is the practice in the Blood Bank, all positive samples were subject to repeat test for confirmation, beforethe seropositive blood unit is discardedThe information extracted from the Dhiraj Hospital blood bank database also included donor Id, Age, Sex,Residential address, donation type, donation frequency.Results: The data analysed in the study consisted of a total 20,711 blood donations, of which 2728 (13.1%)were voluntary and 18,288 (86.9%) were replacement donation.The seroprevalence rate of HIV was 0.1, that of HBV was 1.4, HCV 0.1, syphilis was 0.5 and Malaria was0.3 among all the blood donors. The TTIs were more frequently found in replacement donors in comparisonto volunteer donors.Conclusions:Ø The prevalence of TTI is higher in replacement blood donors than voluntary blood donors, hencecollection of blood from replacement donors should be at least reduced, if not totally eliminated.Ø Stringent criteria need to be used for selection of blood donors.Ø Potential Voluntary blood donors need to be identified and motivated to donate blood regularly.

Investigation of small ruminant brucellosis among smallholder farms: The missing link in control programmes of endemic areas.

Brucellosis is a neglected zoonotic infection with a worldwide distribution and high levels of endemism in some regions, including the Middle East. In Iran, sheep and goats constitute a major part of the livestock population, often kept by small-scale farmers for their own consumption and economic purposes. This investigation aimed at characterizing the Brucella spp. and biovars circulating in sheep and goats under smallholder farming and their potential spillover across farms. For this purpose, from two randomly selected pastoral districts of Alborz and Fars provinces in Iran, a total of 54 aborted foetuses (38 from sheep and 16 from goats) and 528 blood samples were collected from sheep (n=435), goats (n=77), farmers (n=11) and dogs (n=5). Then, serological, bacteriological and molecular characterization of Brucella isolates was performed using standard methods. Our results showed the high seroprevalence of brucellosis in pastoral districts of Fars and Alborz provinces reaching 16.3%, 11.7% and 12.7% by using the Rose Bengal plate test (RBPT), serum agglutination test (SAT) and indirect enzyme-linked immunosorbent assay (iELISA) test, respectively. Furthermore, the results of bacterial culture, conventional biotyping and PCR analyses showed the presence of Brucella melitensis biovar 1 and 2 infections among goat, farmers and dog of the Alborz farms and B.melitensis biovars 1, 2 and 3 among sheep of the Fars farms. Among nine seropositive farmer and dog blood samples (four farmers and five dogs), only three (two farmers and one dog) were positive in both culture and PCR tests. These results stress the need to strengthen screening and control measures in small flocks of small ruminants in Iran that could be the starting point of new outbreaks at the livestock/human interface. The present study also suggests that infected dogs may further maintain the risk of exposure to Brucella pathogens in small farms and beyond.